SCHEMBL7956385

SCHEMBL7956385

COc1cccc(CNc2nnc(-c3c[nH]c4ncccc34)n2N)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.53
FGFR4 P22455 1/20 0.53
CDK2 P24941 7/20 0.47
CDC7 O00311 6/20 0.47
ROCK2 O75116 4/20 0.47
PIM1 P11309 4/20 0.47
PRKACA P17612 4/20 0.47
GSK3B P49841 4/20 0.47
HIPK2 Q9H2X6 4/20 0.47
IRAK4 Q9NWZ3 3/20 0.47
MKNK2 Q9HBH9 2/20 0.47
CLK4 Q9HAZ1 2/20 0.47
ROCK1 Q13464 2/20 0.47
DYRK1A Q13627 4/20 0.47
FLT3 P36888 3/20 0.47
JAK3 P52333 3/20 0.47
CDK9 P50750 3/20 0.47
DAPK3 O43293 2/20 0.47
PRKD3 O94806 2/20 0.47
PAK4 O96013 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2184199 0.86 FGFR1 (0.51) FGFR1FGFR4CDK2CDC7ROCK2
SCHEMBL414462 0.77 FGFR1 (0.67) FGFR1FGFR4CDK2CDC7ROCK2
SCHEMBL1557178 0.77 CDC7 (0.74) FGFR1FGFR4CDK2CDC7ROCK2
SCHEMBL2180364 0.71 FGFR1 (0.53) FGFR1FGFR4CDK2CDC7ROCK2
SCHEMBL857087 0.71 CDC7 (0.64) FGFR1FGFR4CDK2CDC7ROCK2
SCHEMBL857805 0.70 FGFR1 (1.00) FGFR1FGFR4ROCK1TNIKCSF1R
SCHEMBL6517544 0.70 FGFR1 (0.51) FGFR1FGFR4ROCK2CDK9GAA
SCHEMBL857183 0.69 FGFR1 (0.80) FGFR1FGFR4ROCK1TNIKMET
SCHEMBL13887792 0.69 ROCK1 (0.56) FGFR1FGFR4CDK2ROCK2PIM1
SCHEMBL13887774 0.69 ROCK1 (0.60) FGFR1FGFR4ROCK2PRKACAGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466170-B2 7-azaindole derivatives MERCK PATENT GMBH (DE) 2013-06-18 US disclosed
US-8466170-B2 7-azaindole derivatives MERCK PATENT GMBH (DE) 2013-06-18 US disclosed
EP-2303879-B1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-09-05 EP disclosed
US-20110166175-A1 7-AZAINDOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-07-07 US disclosed
US-20110166175-A1 7-AZAINDOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-07-07 US disclosed
WO-2010020308-A1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166175-A1 7-AZAINDOLE DERIVATIVES JAK3, AZI2, MYLK2 FGFR1 434/4885FGFR4 1172/4885CDK2 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.